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Abstract. Many now believe the holy grail for the next stage of therapeutic advance surrounds the development of disease-
modifying approaches aimed at intercepting the year-on-year neurodegenerative decline experienced by most patients with
Parkinson’s disease (PD). Based on recommendations of an international committee of experts who are currently bringing
multiple, potentially disease-modifying, PD therapeutics into long-term neuroprotective PD trials, a clinical trial involv-
ing 198 patients is underway to determine whether Simvastatin provides protection against chronic neurodegeneration.
Statins are widely used to reduce cardiovascular risk, and act as competitive inhibitors of HMG-CoA reductase. It is also
known that statins serve as ligands for PPAR, a known arbiter for mitochondrial size and number. Statins possess multiple
cholesterol-independent biochemical mechanisms of action, many of which offer neuroprotective potential (suppression of
proinflammatory molecules & microglial activation, stimulation of endothelial nitric oxide synthase, inhibition of oxidative
stress, attenuation of -synuclein aggregation, modulation of adaptive immunity, and increased expression of neurotrophic
factors). We describe the biochemical, physiological and pharmaceutical credentials that continue to underpin the rationale
for taking Simvastatin into a disease-modifying trial in PD patients. While unrelated to the Simvastatin trial (because this con-
ducted in patients who already have PD), we discuss conflicting epidemiological studies which variously suggest that statin
use for cardiovascular prophylaxis may increase or decrease risk of developing PD. Finally, since so few disease-modifying
PD trials have ever been launched (compared to those of symptomatic therapies), we discuss the rationale of the trial structure
we have adopted, decisions made, and lessons learnt so far.
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INTRODUCTION26
Parkinson’s disease (PD) is a progressive neu-27
rodegenerative condition with age being the main28
risk factor for its development [1]. With longevity29
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having increased in most Western countries, a con- 30
servative estimation in 2007 predicted that the global 31
number of PD patients will increase to approxi- 32
mately 10 million by 2030 [2]. By 2010, there were 33
approximately 630,000 PD patients in the USA, a 34
figure that was thought set to double by 2040 [3]. 35
However, recent figures suggest these striking predic- 36
tions may themselves be substantial underestimates 37
since the incidence rates for PD now appear to be 38
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increasing each decade [4]. While these figures are39
alarming in themselves, especially given the burden40
to patients and to their families, these demograph-41
ics also demonstrate the massive impact on each42
country’s healthcare services that PD brings.43
For example, the costs in the USA of manag-44
ing PD were estimated in 2013 at $23 million,45
which is $38,000 per patient per year [5], a figure46
to which must be added the additional $10,000 per47
patient/family of indirect costs that their PD incurs48
them. Furthermore, PD patients get progressively49
more expensive to manage as their condition dete-50
riorates over time. Accordingly, increasing annual51
healthcare costs per PD patient are associated with52
more advanced stages of the disease, with greater53
burden resulting from cognitive decline, increased54
non-motor symptoms and development of balance55
impairment and falls. Therefore there is a compelling56
need, shared by patients, families and healthcare sys-57
tems alike, to identify a cost-effective approach to58
intercept disease progression, to slow, stop or even59
reverse neurodegeneration in a rapidly expanding60
global population of PD patients. It is projected that61
if PD disease progression could be slowed by just62
20% it would overall save approximately $76,000 per63
patient, rising to a saving of approximately $440,00064
per patient if PD progression could be stopped alto-65
gether [5]. Both these scenarios would translate to far66
better long-term quality of life for PD patients, as well67
as saving billions of healthcare dollars every year by68
all major Western countries. Currently, only symp-69
tomatic treatments are available to PD patients since70
no disease-modifying therapy has yet been demon-71
strated to be effective in slowing PD progression,72
which highlights what is currently a huge unmet need73
for the identification of effective neuroprotective PD74
therapeutics.75
For this reason, the International PD Linked Clin-76
ical Trials initiative was established in 2012 with77
the specific aim of identifying disease-modifying78
treatments for PD that would slow, stop or reverse79
the neurodegenerative aspects of this condition.80
The International PD Linked Clinical Trials is run81
by a committee of 15 global PD experts who,82
under the stewardship of the Cure Parkinson’s83
Trust, are tasked with selecting, and sending into84
appropriately-designed clinical trials, compelling85
new and repurposed therapeutics to evaluate their86
disease-modifying potential in various different pop-87
ulations of patients with PD. At their first ever88
committee meeting in 2012, 26 potential disease-89
modifying candidate drug approaches for slowing90
PD progression were evaluated. At that meeting, 91
several of these therapeutics were prioritized to 92
enter PD disease-modifying trials, and they have 93
since entered, or have now recently completed 94
(Bydureon), these clinical evaluations. On the basis 95
of compelling biochemical, physiological and phar- 96
maceutical arguments, coupled with a strong safety 97
record, Simvastatin was one of the drugs prioritized 98
at that meeting [6]. Accordingly, funds were sub- 99
sequently raised and this Simvastatin clinical trial 100
in PD patients was commenced in September 2015 101
[7]. This Simvastatin study is co-funded by the Cure 102
Parkinson’s Trust and the JP Moulton Foundation. 103
This on-going 2 year trial involves 198 patients with 104
mid-stage idiopathic PD and is currently being car- 105
ried out in movement disorder units in 23 hospitals 106
across the UK. Projected completion of this trial is in 107
early 2020. 108
The current paper discusses the original biochem- 109
ical, physiological and pharmaceutical rationale that 110
led the committee in 2012 to agree that this trial was 111
strongly merited to explore the disease-modifying 112
potential of Simvastatin for treating PD. It also 113
updates to October 2017 the rationale for conduct- 114
ing this trial in terms of our current understanding 115
of the relevant mechanisms of action and biologi- 116
cal targets of Simvastatin that continues to maintain 117
our enthusiasm about the use of this therapeutic as a 118
disease-modifying approach for patients with PD. 119
This paper also strives to achieve a balanced view 120
of a range of conflicting epidemiological studies 121
surrounding the use of statins for cardiovascular pro- 122
tection, and whether statin use for this purpose may 123
increase or decrease PD risk. 124
Finally, this paper describes details about our ongo- 125
ing Simvastatin trial and outlines the decisions made 126
about its design, as well as aspects about patient 127
selection, patient recruitment, the dose of Simvastatin 128
chosen, investigator site selection, rationale on how 129
the duration of the trial was chosen, and the choices 130
of which patient outcomes are being measured. 131
WHY DOES SIMVASTATIN REPRESENT A 132
STRONG CANDIDATE TO BE A 133
DISEASE-MODIFYING THERAPEUTIC 134
FOR PATIENTS WITH PARKINSON’S 135
DISEASE? 136
What is the biochemical, physiological & phar- 137
maceutical rationale for testing Simvastatin in PD 138
patients as a long-term disease-modifying therapy? 139
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Although statins have been widely adopted in mil-140
lions of patients worldwide as cholesterol lowering141
drugs to reduce cardiovascular risk, a very wide142
range of laboratory studies (described below) coa-143
lesce to suggest that statins also modulate some of144
the important biochemical processes involved with145
driving neurodegenerative changes, and may there-146
fore offer a beneficial long-term disease-modifying147
therapeutic approach to reduce neurological decline148
in PD patients.149
Several laboratory studies have demonstrated mul-150
tiple biochemical neuroprotective effects of statins151
in models of PD; these will be reviewed and dis-152
cussed below. Simvastatin, like all statins, is a specific153
inhibitor of the rate-limiting enzyme in cholesterol154
biosynthesis, and it is one of the most effective of the155
statins in terms of crossing the blood-brain barrier,156
while Pravastatin shows almost no penetration [8].157
In fact the permeability of different statins into the158
brain directly relates to the level of their individual159
lipophilicity [9, 10].160
In addition to their original pharmaceutical use161
in lowering cholesterol, statins display multiple162
neuroprotective effects. For example, Selley [11]163
reported that Simvastatin prevents methyl-4-phenyl-164
1,2,3,6-tetrahydropyridine (MPTP)-induced striatal165
dopamine depletion and protein tyrosine nitration166
in mice. Ghosh et al. [12] then found, at a dose167
of 1 mg/kg body weight/day (which is equivalent to168
the FDA–approved dose in adults), that Simvastatin169
enters the substantia nigra, inhibits the activation of170
p21(ras), suppresses the activation of NF-B, atten-171
uates the expression of proinflammatory molecules,172
protects dopaminergic neurons, restores striatal fibers173
and dopamine levels, and improves locomotor func-174
tion in an acute MPTP model of PD. They concluded175
by suggesting that statins are capable of slowing down176
the progression of neuronal loss in the MPTP mouse177
model.178
In an excellent and extensive review, Roy and179
Pahan in 2011 [13] outlined the evidence for five sep-180
arate pathways, each thought to be of relevance in181
PD neurodegenerative aetiopathogenesis, by which182
Simvastatin may improve dopaminergic neuronal183
survival :-184
• suppression of proinflammatory molecules and185
microglial activation186
• stimulation of endothelial nitric oxide synthase187
• inhibition of oxidative stress188
• attenuation of -synuclein aggregation189
• modulation of adaptive immunity190
One of the objectives of the current review is to 191
update these biochemical and pharmaceutical find- 192
ings to the present day to help give a perspective 193
on the rationale of why a clinical trial testing Sim- 194
vastatin as a potential disease-modifying therapeutic 195
for patients with PD is currently underway. Below is 196
our current interpretation (updated to October 2017) 197
of the multiple cholesterol-independent biochemical 198
mechanisms of action of Simvastatin as originally 199
cited by Roy and Pahan in 2011 [13] that we believe 200
specifically support the biochemical, physiological 201
and pharmaceutical reasons underpinning this inno- 202
vative clinical trial. We add to this 2011 list, the topic 203
of the stimulation of increased expression of neu- 204
rotrophic factors by statins which was not covered 205
by Roy & Pahan in 2011 but since then, in the con- 206
text of neurodegenerative diseases, has shown also to 207
be of considerable relevance to the other pleliotropic 208
effects of statins mentioned above. 209
Suppression of proinﬂammatory molecules and 210
microglial activation 211
In 2011, Roy & Pahan [13] collated evidence that 212
inflammation and oxidative stress represent impor- 213
tant components in nigrostriatal degeneration in PD 214
[14–20]. At that time it was already well established 215
that cytokines were central to the inflammatory pro- 216
cesses that accompany various forms of acute and 217
chronic brain injury, and many research laboratories 218
around the world had begun to focus with therapeu- 219
tic intent on PD. Ghosh et al. [19] also notably found 220
that NF-kappaB was activated within the substantia 221
nigra pars compacta of PD patients and in MPTP- 222
intoxicated mice. Roy and Pahan [13] then discussed 223
how statins might be harnessed to reduce neuroin- 224
flammation in a Parkinsonian context. 225
At that time, the evidence for this potentially 226
important property of statins was that Pahan et al. 227
[21] had already shown Lovastatin inhibits NF-κB, 228
iNos expression and the proinflammatory cytokines, 229
TNF-, IL-1 and IL-6 in lipolysaccharide (LPS)- 230
stimulated rat primary astrocytes. Adding to earlier 231
work by Stanislaus et al. [22], Neuhaus et al. [23] 232
using in cells taken from multiple sclerosis patients 233
demonstrated that Simvastatin is more potent as 234
an effective immunomodulatory agent than either 235
Lovastatin and Mevastatin. 236
To add to this, Clarke et al. [24], building 237
on the fact that they knew statins generate pow- 238
erful anti-inflammatory effects in brain, reported 239
that Atorvastatin exerts these effects via IL-4, and 240
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completely independent of its cholesterol-lowering241
actions. These results were supported by other find-242
ings [12, 25] which showed how p21(ras) inhibits the243
expression of iNOS by inhibiting the activation of244
NF-kappaB, while Pahan et al. [21, 26] demonstrated245
how farnesylation can impact on these biochemi-246
cal processes, and how the sphingomyelin-ceramide247
signaling pathway is involved with stimulating the248
expression of iNOS via LPS- or cytokine-mediated-249
activation of NF-kappaB in astrocytes. The current250
state of knowledge at that time on these aspects had251
been well described and summarized by van der Most252
et al. [27], after which Santiago et al. [28] then showed253
that Simvastatin protected striatal dopaminergic ter-254
minals against the neurotoxic damage caused by LPS,255
but not in an MPP+ toxic model. Liu et al. [29] have256
recently explored how the inflammatory responses in257
microglia may be controlled in PD-related models258
and postulating that Nur77 may be a modulator of259
microglia-mediated dopaminergic neurotoxicity.260
Building on earlier work which showed that statins261
protect neurons in models of long-lasting status262
epilepticus and seizures, Gouveia et al. [30] found263
thatLovastatinprotectively decreased mRNA expres-264
sion levels of the proinflammatory cytokines, IL-1,265
IL-6, and TNF in hippocampal neurons during266
experimental status epilepticus. Using a mouse model267
of Alzheimer’s disease (AD), Kurata et al. [31] found268
that, after 15–20 months of treatment, both Atorvas-269
tatin andPitavastatinwere protective of senile plaque270
formation, and that this protection was preceded by a271
reduction of proinflammatory events including levels272
both of activated microglia and TNF-. This sup-273
ported earlier work by Tong et al. [32] who had274
found in amyloid precursor protein transgenic mice275
that Simvastatin attenuated inflammation, oxidative276
stress and reduced amyloid beta levels and the num-277
ber of affected neurites. Simvastatin had also been278
shown to protect against tissue injury in the context279
of ischemia-reperfusion injury [33], and in a model280
of cardiopulmonary bypass to protect against cere-281
bral and systemic inflammation, neuronal loss and282
memory impairment [34].283
Using a 6-hydroxydopamine model of PD and284
a 3 week administration of Simvastatin, Yan et al.285
[35] presented evidence that NMDA receptor mod-286
ulation, MMP9 (matrix metalloproteinase-9) and287
TNF- by Simvastatin could partially explain its288
anti-inflammatory, neuroprotective effects. Using a289
similar model of PD, Kumar et al. [36] then found in290
a mixed behavioral and biochemical study that Ator-291
vastatin (20 mg/kg) and Simvastatin (30 mg/kg) were292
both protective of weight loss, locomotor activity, and 293
also decreased levels of the inflammatory cytokines, 294
TNF- and IL-6 that are characteristic of this model. 295
They also found that these statins restored the deficits 296
in mitochondrial enzyme complex activity that are 297
also generated in their 6-hydroxydopamine model. 298
The notion that mitochondrial function might be 299
involved with the anti-inflammatory action of statins 300
was also highlighted by Esposito et al. [37] in a com- 301
pletely different model, that of spinal cord injury 302
(which also displays inflammation, neutrophil infil- 303
tration, nitrotyrosine formation, pro-inflammmatory 304
cytokine expression, and nuclear factor (NF)-κB 305
activation). They showed that PPAR- (a major 306
arbiter of mitochondrial size and number) contributes 307
to the anti-inflammatory activity of Simvastatin. 308
Specifically, and describing their findings as the 309
demonstration of a new mechanism for the action of 310
statins, they showed that the anti-inflammatory prop- 311
erties of Simvastatin were substantially reduced in 312
a PPAR- knockout model. Since, as well as over- 313
all mitochondrial function, the PPAR-alpha nuclear 314
receptor also regulates genes involved with inflam- 315
mation and oxidative stress, it is of particular 316
interest that they found PPAR- mediates the anti- 317
inflammatory effects of Simvastatin in vivo models of 318
acute neuroinflammation. This built on their earlier 319
observation [38] that Simvastatin similarly worked 320
in synergy with PPAR- to protect cellular damage 321
caused by systemic inflammation in a model of mul- 322
tiple organ failure. A recent report by Zhou et al. 323
[39] expands Esposito’s findings in that they showed 324
Simvastatin is both neuroprotective and inhibits 325
secondary inflammatory damage by markedly down- 326
regulating the expression of the proteins (NF)-κB, 327
TLR4 and IL-1. 328
Xu et al. [40] studied how Simvastatin affects 329
6-hydroxydopamine-lesioned PC12 through regula- 330
tion of PI3K/AKT/caspase 3 and by modulating 331
inflammatory mediators, and how it might be used 332
therapeutically to treat patients with PD. In a cel- 333
lular RNA study involving 6-OHDA administration, 334
Yan et al. [41] explored the involvement of N-methyl- 335
D-aspartic acid receptor 1 (NMDAR1) finding that 336
Simvastatin inhibits the expression of NMDAR1, 337
and of the cytokines, TNF-, IL-1, and IL-6, in 338
a manner just as potent as using siRNA for the 339
receptor. In a retinal cell model, Zhang et al. [42] 340
reported that that Simvastatin inhibits apoptosis fol- 341
lowing IR-induced retinal injury by inhibition of 342
the TNF-/NF-κB pathway. With a PD therapeu- 343
tic perspective in mind, Zhang’s findings should be 344
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seen in the context that Malu Tansey’s group had345
previously described [43] how the TNF-/NF-κB346
pathway mediates chronic inflammation which, in347
turn may generate a reduction in Parkin levels, and348
thereby increasing the vulnerability for degeneration349
of the nigrostriatal pathway. They argued that chronic350
inflammation offers a clear biochemical mechanism351
which can promote the development of PD. Huang352
et al. [44] recently showed in multiple models that353
Simvastatin ameliorated memory deficits in patients354
with Alzheimer’s disease as well as in laboratory355
models of AD, and that it achieved this through356
reduction of mRNA expression of inflammatory357
cytokines and mediators as well as by improv-358
ing neuronal survival, supporting earlier work by359
Wang et al. [45].360
In summary, by directly inhibiting key inflamma-361
tory processes, Simvastatin may therefore represent362
a therapeutically beneficial disease modifying agent363
with considerable potential to reduce the rate of PD364
progression.365
Stimulation of endothelial nitric oxide synthase366
Roy & Pahan [13] also collated robust evidence367
[14-15, 17, 21, 24-25] in 2011 which supported the368
view that the upregulation of endothelial nitric oxide369
synthase (eNOS) is generated by statins via suppres-370
sion of mevalonate and concomitant activation of the371
PI-3 kinase-AKt pathway. This built on Flint Beal’s372
supposition [46] that modulating eNOS might offer373
a valuable neuroprotective therapeutic approach for374
the treatment of PD. Statins inhibit iNOS expression,375
while in contrast, they stimulate eNOS-derived nitric376
oxide production, and this property appears biochem-377
ically unrelated to their ability to reduce cholesterol378
[47]. Statin-induced upregulation of eNOS can be379
reversed by geranylgeranyl pyrophosphate (but not380
by farnesyl pyrophosphate) which intimates [13]381
that Rac/Rho (rather than Ras) may be involved382
in the regulation of eNOS. Fulton et al. [48] and383
Skaletz-Rorowski et al. [49] demonstrated that Akt384
phosphorylates eNOS, while mevalonate inhibits385
phosphatidylinositol-3 kinase and thereby reduces386
Akt activation. As statins lower mevalonate levels387
(via inhibition of HMG-CoA reductase) it therefore388
seems likely that reduction of mevalonate may trigger389
increased eNOS production, and thereby increasing390
NO levels. Atorvastatin has been shown [50, 51]391
to promote NOS-derived nitric oxide production by392
reducing expression of caveolin-1, and the therapeu-393
tic implications of these HMG-CoA reductase effects394
of statins are still being actively clarified in cardio- 395
vascular medicine [52, 53]. 396
A recent review by Saeedi Saravi et al. [54] focuses 397
more specifically on the potential relevance of the 398
mevalonate pathway to the potential therapeutic ben- 399
efit that statins may offer in protecting against long 400
term neurodegeneration in PD patients. Bezard’s 401
group [55] now consider downstream modulation 402
of the sterol regulatory element-binding protein 1 403
(SREBP-1) pathway to be important in inducing 404
phenotypic changes in dopaminergic cells, includ- 405
ing increases in cell growth, synaptic connections 406
and protein expression. They have recently presented 407
additional data on this that supports a potential pro- 408
tective role of statins in PD [56]. Since SREBP-1 (and 409
SREBP-2) regulates promotor activity of PCSK9 [57] 410
there is therefore a clear link, with therapeutic impli- 411
cations, between SREBP-1 and PCSK9, and it was 412
recently shown that Simvastatin increases PCSK9 413
expression [58, 59] which may be therapeutically 414
relevant [60–63]. 415
Sun et al. [64] showed in a cardiovascular context 416
that eNOS is a direct target of miR-155. Inflam- 417
matory cytokines such as TNF- increase miR-155 418
expression and inhibition of miR-155 reverses TNF- 419
-induced downregulation of eNOS expression. 420
They found that Simvastatin decreased TNF-- 421
induced upregulation of miR-155 and ameliorated 422
the effects of tumor necrosis factor- on eNOS 423
via the mevalonate-geranylgeranyl-pyrophosphate- 424
RhoA signaling pathway. 425
Pierucci et al. [65] reviewed in 2011 the promise 426
and opportunities of harnessing the NOS system to 427
treat PD, essentially building on the work by Hoang 428
et al. [66] who assessed the aspects and extent of the 429
nitrative damage, including in nuclear and mitochon- 430
drial DNA, that is caused in an MPTP model of PD, 431
and in a NOS knockout model, and from which they 432
concluded DNA damage may contribute to the over- 433
all neurodegenerative process in PD. Peter Jenner’s 434
group [67] found evidence of a major role for i-NOS- 435
mediated nitrative stress in microglia in their MPP+ 436
model of PD, which they concluded had important 437
implications for developing neuroprotective strate- 438
gies for PD, an argument which was further supported 439
by Tripathy et al. [68], and also recently reviewed by 440
Jime´nez-Jime´nez et al. [69] from the perspective of 441
studies both in PD patients, and in various PD models. 442
Li et al. [70] reported in 2015 how Simvastatin 443
is therapeutically beneficial following LPS-induced 444
experimental lung injury, showing it had a protec- 445
tive effect by alleviating lung injury via decreasing 446
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iNOS levels. This ties in with the earlier findings447
by Pahan et al. [21] who, as described above, had448
already demonstrated that Lovastatin inhibits NF-κB,449
iNOS expression and the proinflammatory cytokines,450
TNF-, IL-1 and IL-6 in LPS-stimulated rat primary451
astrocytes.452
Therefore, as well as its beneficial effects through453
suppression of proinflammatory molecules and454
reduction of microglial activation (as outlined in the455
previous section), Simvastatin also appears to offer456
substantial long-term disease-modifying benefits for457
PD patients on the basis of decreasing microglia458
iNOS levels and reducing chronic nitrative stress.459
Along with the continued research into how NOS460
may contribute to the neurodegenerative process in461
PD, and may thus offer a therapeutic opportunity,462
such as using Simvastatin, to delay PD progression,463
a parallel line of research has explored how NOS464
might be modulated for therapeutic benefit in treat-465
ing a widespread clinical complication experienced466
by many PD patients on long-term dopaminergic467
support, that of L-DOPA-induced dyskinesias. How468
NOS inhibitors might be employed in the treatment469
of dyskinesias has been explored in experimental470
studies using various PD models [71–74], and is471
clearly showing promise for clinical translation for472
the treatment of dyskinesias in PD patients. The473
basis for this [75, 76] is that when inhibitors of the474
MAPK signaling cascade impede the inappropriate475
dyskinesia-inducing response of striatal neurons this476
offers considerable evidence that MAPK inhibitors477
may offer therapeutic efficacy in reducing incidence478
and/or severity of dyskinesias experienced by PD479
patients.480
The isoprenylation of Ras is inhibited by statins481
which underpins their ability to curb the stimulation482
of ERK 1/2 MAP kinases, and Schuster et al. [77]483
found that Lovastatin reduces the number and sever-484
ity of dyskinesias in their 6-OHDA model of PD. In485
particular, Tison et al. [78] found that Simvastatin was486
indeed effective in reducing dyskinesias in a monkey487
model of PD, but only at high doses that would be488
incompatible with their long-term administration in489
man, and which were 3-6 times higher than is being490
used in the current clinical trial of Simvastatin in PD491
patients (see below).492
Inhibition of oxidative stress493
Roy & Pahan [13] reviewed the evidence for494
the involvement of statins in inhibiting the pro-495
cess by which oxidative stress contributes to496
neurodegeneration in PD, particularly focusing on 497
the roles of nicotinamide adenosine dinucleotide and 498
Rac, collating evidence that NADPH oxidase is vital 499
in terms of attrition of dopaminergic neurons. In fact 500
it was already known that nigral NADPH oxidase 501
is upregulated in MPTP mice, but that, conversely, 502
this toxin had no effect on dopaminergic neurons 503
in gp91phox (–/–) mice [79, 80]. Building on the 504
review by van der Most et al. [27], Roy & Pahan 505
[13] provided evidence that the inhibition by statins 506
of the geranylgeranylation of Rac leads to reduced 507
NADPH oxidase-mediated generation of superoxide, 508
which they interpreted as evidence statins may atten- 509
uate oxidative stress by diminishing the production of 510
reactive oxygen species both in the substantial nigra 511
of MPTP mice, and in PD patients via this biochem- 512
ical process. 513
Since then, much research has focused on the 514
role of Nrf2 (nuclear factor erythroid 2-related fac- 515
tor 2) in oxidative stress [81, 82], and how, in several 516
therapeutic areas, including PSP and PD [83], age- 517
related macular degeneration [84], oncology [85, 86], 518
cardiovascular disease [87, 88], arterial calcification 519
[89], spinal cord injury [90] and radiation dermati- 520
tis [91], this emerging biochemical insight might 521
be manipulated to therapeutic advantage. Nrf2 is 522
a cytoprotective master regulator of the transcrip- 523
tional response to oxidative stress; it has a rapid 524
turnover, and its role in neurodegenerative diseases 525
has been well described by Gan and Johnson [92], 526
and its diversity of actions and control with respect to 527
mitochondrial function were recently well reviewed 528
by Holmstrom et al. [93], and also by Dinkova- 529
Kostova et al. [94]. When reactive oxidative species 530
are at low levels, nuclear Nrf2 is suppressed by the 531
inhibitory protein, KEAP1, which sequesters Nrf2 in 532
the cytoplasm to prepare it for proteasomal degrada- 533
tion [95, 96], and which maintains Nrf2 at a relatively 534
low steady state level. However, increasing levels of 535
reactive oxidative species influence KEAP1 in a way 536
that progressively impairs its ability to target Nrf2 for 537
degradation. A link between Nrf2, MAPT expression 538
and the risk of PD has recently been postulated by 539
Wang et al. [97], and may possibly offer a mechanis- 540
tic glimpse of why tau/MAPT repeatedly appears in 541
large-scale GWAS studies of PD patients [98, 99] yet 542
its role in the generalized risk of developing PD, and 543
its specific role in neuroinflammation with regards to 544
PD, are both poorly understood [100]. 545
Several agents (particularly Nrf2 activators), which 546
act on these biochemical pathways (by upregu- 547
lating antioxidant, anti-inflammatory, mitochondrial 548
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biosynthetic, apoptotic mediator and cytoprotective549
genes) have promising potential for the long-term550
protection from neurodegeneration in PD patients.551
These include monomethylfumarate [101], dimethyl-552
fumarate [102], gliptins [103] and the triterpenoid,553
RTA-408 [85], each of which have already been prior-554
itized by the International PD Linked Clinical Trials555
committee to enter clinical trials in PD patients to556
determine their disease-modifying potential. As a557
practical therapeutic approach in neurology, much558
of the new understanding of the protective poten-559
tial of activating Nrf2 resides in these emerging560
publications and it is being rapidly translated into561
disease-modifying agendas in PD. as well as in other562
therapeutic areas. Urate probably also acts via the563
Nrf2 antioxidant response pathway [104] and is cur-564
rently being tested (using oral inosine) in a Phase565
III trial in 270 PD patients to assess its disease-566
modifying potential over a treatment duration of 2567
years [105]. To add to all the other biochemical568
actions of statins outlined in this review we can add569
another LCT-prioritized drug, Simvastatin, to this570
important list of Nrf2 activators that may all have571
the potential to be used clinically to slow neurode-572
generation in PD patients. In 2014 Abdanipour et al.573
[106], studying PGC-1 and Nrf2 expression on cell574
survival and apoptosis demonstrated that Lovastatin575
protects bone marrow stromal cell-derived neural576
stem cells against oxidative stress-induced cell death,577
and suggested it as a candidate for the treatment of578
neurological diseases that involve oxidative stress.579
Since then, several papers have added further sup-580
port to the view that statins act as Nrf2 activators. Wu581
et al. [107] recently reported thatAtorvastatin reduces582
damage in liver injury when exposed to inflammatory583
stress, citing loss of the adaptive antioxidant response584
mediated by Nrf2 as the basis for the biochemical585
mechanism involved. Simvastatin was found by Jang586
et al. [108] to induce heme oxygenase-1 via direct587
activation of Nrf2 in human colon cancer cell lines.588
Ferraro et al. [109] studied the effects of Simvastatin589
in both lung inflammation and in a human neuroblas-590
toma cell line and concluded that Simvastatin may591
provide neuroprotection against neurotoxicity via592
Nrf2 independently of its ability to inhibit cholesterol593
synthesis. Furthermore, Yeh et al. [110] demonstrated594
that the well known effect of statins to protect against595
atrial fibrillation was generated by the activation of596
Akt/Nrf2/heme oxygenase-1 signaling.597
Hsieh et al. [111] was the first to show that iron598
production from Heme oxygenase-1 activity may599
play an important role in the increased apoptosis600
in response to glucose deprivation in neuronal cells 601
pretreated with Simvastatin which acted by inducing 602
of Heme oxygenase-1, a process which was medi- 603
ated by Nrf2. They found in neuronal cells that the 604
iron chelator, desferrioxamine, blocked apoptosis, 605
which suggested that iron production from Heme 606
oxygenase-1 activity might drive increased apoptosis 607
in situations of glucose deprivation in neuronal cells 608
that had been pretreated with Simvastatin. Two PD 609
trials also prioritized by the international PD Linked 610
Clinical Trials committee in 2012 are underway to test 611
iron chelator therapy as a potential disease-modifying 612
treatment for patients with PD. One trial involves 338 613
early-stage PD patients who are not currently taking 614
antiparkinsonian medication (disease duration less 615
than 18 months) and who are taking the iron chela- 616
tor, Deferiprone [112], and the second dose-finding 617
trial [113], also using Deferiprone, is comprised of 618
140 PD patients who have been diagnosed with PD 619
within the last 3 years and who are currently taking 620
antiparkinsonian medication. 621
Attenuation of α-synuclein aggregation 622
In their 2011 review of the potential for using 623
statins to treat PD, Roy and Pahan [13] summarized 624
the knowledge at that time relating to how alpha- 625
synuclein impacts on dopaminergic toxicity and cell 626
loss, motor deficits, the synthesis of cholesterol, and 627
the deposition of alpha-synuclein-rich Lewy bod- 628
ies in the substantia nigra. They concluded that, 629
since statins suppress the release of proinflammatory 630
molecules from activated glial cells (see above), it 631
is likely they should also subdue malformed alpha- 632
synuclein-mediated glial cell activation in a manner 633
that is completely independent of cholesterol. As with 634
all the other sections in this review, much has moved 635
on over the past 6 years. A current view, held by many 636
(but not in 2011) is that malformed alpha-synuclein is 637
capable of cell-to-cell transmission and that this may 638
underpin the development of PD throughout the body, 639
but particularly involving spread from the enteric 640
nerves, and/or olfactory bulb, to the substantia nigra, 641
raphe, locus coeruleus, the cortex and several other 642
important anatomical sites which each contribute in 643
their own way to the range if PD symptoms we see 644
clinically [114–118]. 645
Roy and Pahan [13] reflected on how Lovas- 646
tatin, Simvastatin and Pravastatin each generate 647
large reductions in alpha-synuclein accumulation 648
both in a transfected neuronal cell line, and in 649
primary human neurons [119], and that oxidized 650
Un
co
rre
cte
d A
uth
or
 P
ro
of
8 C.B. Carroll and R.K.H. Wyse / Simvastatin as a Potential Disease-Modifying Therapy
cholesterol even promotes increased alpha-synuclein651
aggregation [120]. This observation has recently been652
somewhat supported by Eriksson et al. [121] who653
interpreted their findings in a neuroblastoma cell line654
exposed to MPP+ to reason that high cholesterol in655
PD stimulates the accumulation of alpha-synuclein.656
Once Lovastatin was also shown [122] to reduce657
alpha-synuclein accumulation and aggregation in658
transgenic models, it was logical to contemplate that,659
since statins lower cholesterol levels, then they may660
therefore directly reduce the aggregation of alpha-661
synuclein in PD patients. Koob et al. concluded662
that, while it was known as early as 2006 [123]663
that, once mutated, alpha-synuclein causes a much664
stronger glial cell inflammatory response, but that665
since statins reduce the expression of these proinflam-666
matory molecules they may well be found beneficial667
as a long-term treatment for patients with PD. Given668
the knowledge available at that time, Roy and Pahan669
[13] therefore posed the logical question; do statins670
suppress mutated alpha-synuclein-mediated glial cell671
activation in a manner that is completely indepen-672
dent of cholesterol? Several papers, mostly published673
since then, have gone some way to answering that674
question [24, 124–131] – the widely-held consensus675
answer is definitely yes, although there is still slightly676
less clarity on the mechanistic details than we might677
have wished for.678
Modulation of adaptive immunity679
Statins have been repurposed into several diseases680
where innate and adaptive immunity and endothelial681
damage play an important role [132]. To date, statins682
have been specifically tested and used in atheroscle-683
rosis [133], multiple sclerosis [134, 135], rheumatoid684
arthritis [136], Behcet’s disease [137], and Kawasaki685
disease [138, 139] in many cases with very promis-686
ing results. It was pointed out in the review by Roy687
& Pahan [13] that effector T cells may exacerbate688
disease progression (which can be demonstrated in689
post mortem PD brains), while regulatory T cells690
(Tregs) tend to occupy a protective role. It has been691
found that T-cell responses in an MPTP model of692
PD add to the rate of neurodegeneration [140–142]693
while conversely, Tregs have been shown to be protec-694
tive in an MPTP model of PD [143], and the reasons695
behind this duality have previously been discussed696
by Mosley et al. [144] and, since Tregs can be mod-697
ulated in vivo, this gives strong support to the use698
of an immunomodulatory approach to treat PD. In699
2010, Reynolds et al. [145] demonstrated that natural700
Tregs reversed the T cell nigrostriatal degeneration 701
caused by malformed alpha-synuclein, proposing that 702
this observation forms a sound rationale for future 703
PD immunization strategies. This approach has been 704
reviewed and expanded upon by several with consid- 705
erable clarity and insight [124, 130, 146, 147], and 706
most recently by Gendelman and Mosley [148] who 707
discussed approaching this topic in therapeutic terms 708
by postulating simultaneously to seek enhancing the 709
suppressive function of Tregs, while downregulating 710
proinflammatory cytokine production. They balanced 711
and tempered this by recognizing that immune system 712
activation is also necessary in order to clear debris 713
to help sustain and restore damaged neurons. They 714
offered ‘mounting and strong evidence’ that immune 715
transformation can affect the pathogenesis of neu- 716
rodegenerative diseases, and that modulation of the 717
inflammatory response, while restoring a homeostatic 718
immune system via immunopharmacological strate- 719
gies, may lead to new therapeutic opportunities for 720
PD and other neurodegenerative disorders. 721
Acting as a cytokine and neuropeptide which 722
impacts on immune responses, Vasoactive Intesti- 723
nal Peptide (VIP) induces Tregs. The neuroprotective 724
capability of Tregs is mediated through TH17, and It 725
has been suggested that shifting the balance between 726
effector and regulatory T cell activity by adaptive 727
immune regulation of glial homeostasis could be used 728
to attenuate neurotoxic inflammatory events [149]. 729
By peptide modifications similar to those for GLP- 730
1 agonists that have given them greater potency and 731
much longer metabolically stable half-life in blood 732
than the native hormone, Olsen et al. [150] developed 733
an analogue of VIP and showed that to be an effective 734
immunomodulatory agent in an MPTP model of PD. 735
They concluded by stating they had provided “strong 736
evidence” that VIP receptor agonism has the potential 737
to slow the pathogenesis of PD through modulation 738
of the inflammatory response. This builds on the ear- 739
lier observation by Brachmachari and Pahan [151] 740
who, and citing Foxp3 as a master regulator in Treg 741
formation and function, discovered that Simvastatin 742
upregulates Foxp3 by inhibiting nitric oxide produc- 743
tion, going on to suggest that Treg enrichment by 744
Simvastatin may help to protect dopaminergic neu- 745
rons in the substantia nigra. 746
Increased expression of neurotrophic factors 747
This potential biochemical effect of statins was not 748
covered in the earlier review by Roy & Pahan [13]. 749
Hernandez-Romero et al. [152], as well as demon- 750
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strating the potency of Simvastatin in markedly751
reducing inflammatory responses in LPS-induced PD752
rats, including interleukin-1, TGF- and iNOS (as753
have several other groups, as described above), also754
found that Simvastatin stimulated the activation of the755
neurotrophic factor, BDNF. This suggests there may756
be a profoundly neurogenic aspect to the mechanism757
of action of Simvastatin in dopaminergic neurons.758
This was followed up by Wu et al. [153] who showed759
that Simvastatin increases the hippocampal expres-760
sion of BDNF and VEGF in a model of brain injury.761
They concluded that the neurorestorative effect of762
Simvastatin they observed was probably be medi-763
ated via the Akt-mediated signaling pathway, which764
thereby upregulated expression of growth factors,765
thus stimulating via neurogenesis the restoration of766
cognitive function they observed with Simvastatin.767
They employed a similar dose to that used in our768
current clinical trial of Simvastatin in PD patients769
(see below). It was then reported [154] in a model770
of spinal cord injury that Simvastatin generated sig-771
nificantly improved locomotor recovery, and this772
improvement was ascribed to the higher levels of773
expression of BDNF and GDNF which observed774
in this study after administration of Simvastatin.775
This contention was further supported when it was776
reported [155] that both Simvastatin and Atorvastatin777
increased the expression of BDNF, VEGF and NGF,778
as well as activation of the Akt-mediated signaling779
pathway, in an experimental model of intracerebral780
hemorrhage. Furthermore, it was shown [156] that781
Simvastatin modulates the profile of the release of782
cytokines and trophic factors from microglia, (partic-783
ularly interleukin-1, TNF-, and BDNF) through a784
mechanism that is cholesterol-dependent, and which785
went some way to explain previously confusing con-786
tradictions in laboratory results. Rana et al. [157]787
then reported that Simvastatin increased expression788
of BDNF exon-IIC transcripts in stressed mice. Wang789
et al. [158] then reported that, in A25-35-mice,790
Simvastatin is protective of neurogenesis through791
reduction of farnesyl pyrophosphate level which792
then generates 7nAChR-cascading PI3K-Akt and793
increased levels of BDNF. Next, Gao et al. [159]794
demonstrated that Simvastatin significantly increases795
the levels both of BDNF and GDNF in a model of796
spinal cord injury, and then went on to show that797
Simvastatin also reduces neuronal apoptosis while798
promoting locomotor recovery in this model [160]. It799
was recently shown [161] that Simvastatin promoted800
the neurogenesis and migration of neural stem cells801
with a mode of action involving the ROCK/CGTase802
pathway. Simvastatin has also recently been demon- 803
strated to improve peripheral nerve regeneration and 804
functional recovery in an experimental model of sci- 805
atic damage that involves elevation of levels of GDNF 806
and several other growth factors [162]. Earlier this 807
year, it was reported [163] that Atorvastatin increased 808
serum BDNF levels and improved functional recov- 809
ery (modified Rankin and Barthel scales) in patients 810
following atherothrombotic stroke. 811
It had previously highlighted [20] that the 812
Nurr1/CoREST pathway in microglia and astrocytes 813
protects dopaminergic neurons from inflammatory 814
damage, and this is thought to be particularly relevant 815
here because Nurr1 activity is known to be closely 816
related to GDNF activity [164]. Wang et al. [158] also 817
demonstrated that Simvastatin induces autophagy by 818
inhibiting the mTOR signaling pathway. In 2015, Roy 819
et al. [165] then took a step forward to help tie the 820
various threads together in reporting that statins serve 821
as ligands for PPAR and ascribed the neurotrophic 822
action of statins to be via the PPAR-CREB path- 823
way. Until then there had been no receptor protein 824
identified for statins (they exert their lipid-lowering 825
actions quite differently, more structurally, as com- 826
petitive inhibitors of HMG-CoA reductase). 827
Finally, and here focusing on PD, unlike most of 828
the other neurological models described in this sec- 829
tion from which we are definitely able to draw useful 830
parallels, Castro et al. [166] reported on how Ator- 831
vastatin in an intranasal PD rat model caused in a 832
significant increase in striatal and hippocampal lev- 833
els of nerve growth factor, adding that their findings 834
‘extend the notion of the neuroprotective potential 835
of Atorvastatin and suggest that it may represent a 836
new therapeutic tool for the management of motor 837
and non-motor symptoms of PD’, while in 2016, 838
Tan et al. [167] showed in an LPS model of PD 839
that Simvastatin restored the expression of BDNF, as 840
well as replicating earlier findings by many groups 841
that it reduces oxidative stress and improves nigral 842
function. 843
EPIDEMIOLOGICAL STUDIES ON THE 844
USE OF STATINS AND THE RISK OF PD 845
The purpose of this section is not intended as a 846
critical appraisal of epidemiological research in this 847
area, nor to generate data synthesis (in fact others 848
have previously attempted to do this - see below), 849
but rather to provide a catalogue, and a context, of 850
published studies. 851
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Valid interpretation of published studies has been852
consistently confounded by the core reason why853
statins are taken, i.e., to reduce high levels of choles-854
terol, which in turn means there is inevitably a high855
correlation between the two explanatory variables,856
statin use and blood cholesterol levels. Partly because857
of this confounding inter-relationship, there is cur-858
rently no clarity about whether statin use is protective859
of an individual developing PD, has no effect, or860
makes it more likely that an individual may develop861
the disease.862
Most would agree that the hypothetical risk of863
a healthy individual acquiring PD through taking864
a particular medication, represents a very different865
scenario to using that same medication to treat the866
disease once it has already developed. Nevertheless,867
it is appropriate to discuss here, and bring a balance868
to, the various studies that have either linked the tak-869
ing of statins to protecting healthy individuals against870
developing PD, or the converse.871
We re-emphasize this ongoing epidemiological872
debate is actually of questionable relevance to873
patients who already have PD but it is appropriate874
in terms of our on-going trial of Simvastatin to use875
this opportunity to give a balanced scientific review876
of the viewpoints, the available evidence, and to high-877
light strengths and weaknesses in published papers in878
this area of research.879
First, it is important to make the point that, since880
the initial isolation of statins from microorganisms881
in the 1970s, there has been a huge growth in their882
specific use in primary and secondary prevention of883
various forms of cardiovascular disease. In 2016, the884
US Preventative Services Task Force advised the use885
of statins for people between 40 and 75 years old886
who carry at least one risk factor for heart disease,887
and who have more than a 10% risk of heart dis-888
ease [168]. Similarly, the UK National Institute for889
Health and Clinical Excellence has endorsed the use890
of statins in those with an estimated 10% risk of devel-891
oping cardiovascular disease over the next decade892
[169]. The nature, interactions and pharmacokinetic893
relationships between cholesterol, apolipoproteins894
and statins were well described from a neurolog-895
ical perspective in a Cochrane review [170, 171]896
as a part of an original, then updated, analysis to897
consider the possible use of statins in the context898
of dementia prevention or treatment. They found899
‘insufficient evidence to recommend statins for the900
treatment of dementia’. Many PD patients develop901
cognitive impairment, but while none of those in902
that meta-analysis were PD patients, a recent paper903
by Deck et al. [172] found that PD patients taking 904
statins performed better on tests of global cognition, 905
semantic fluency and phonemic fluency. Further- 906
more, although it is known that statins increase HDL 907
and apolipoprotein A1 levels [173, 174], and that 908
lower apolipoprotein A1 levels are associated with 909
later stages of PD progression, Deck did not find that 910
baseline apolipoprotein A1 levels correlated with any 911
baseline neuropsychological measures. 912
Turning now to the question of whether the use 913
of statins may positively or negatively influence the 914
risk of developing PD, in 2006 and citing that epi- 915
demiologic investigations had revealed an association 916
between low LDL-C levels and the risk of PD, with 917
several studies previously having suggested a role 918
of lipid and cholesterol metabolism in the patho- 919
genesis of PD, de Lau et al. [175], studying >6000 920
patients, felt there might well be a role involving 921
lipids in the pathogenesis of PD, and suggested that 922
this provided support for the notion of an important 923
role of oxidative stress in the pathogenesis of the 924
disease. 925
An extensive review of patients in the Veterans 926
Affairs healthcare system then found Simvastatin (but 927
not Atorvastatin or Lovastatin) use was associated 928
with a strong reduction in incidence of dementia 929
and PD [176]. Wahner et al. [177] then found that 930
all statins are inversely associated with PD (except 931
for Pravastatin). They observed a higher frequency 932
of statin use among controls versus PD cases. The 933
strongest protective association between statin use 934
and PD was observed in long-term (>5 yr) statin users. 935
Huang et al. [178] then reported the results of a small 936
epidemiological study of 124 PD patients and 110 937
controls which inferred that low LDL-C may be asso- 938
ciated with a higher occurrence of PD, and that statin 939
use for prophylactic cardiovascular protection may 940
lower PD occurrence. What Huang did not report is 941
whether their patients had low LDL levels prior to 942
their diagnosis of PD, nor whether their LDL lev- 943
els decreased after this diagnosis. Therefore, since 944
statins are effective at lowering LDL cholesterol lev- 945
els, it may well be that their study design intrinsically 946
confused cause with effect. What is more is that this 947
research was vastly underpowered in the sense that 948
fewer than 20 of the 124 PD patients in this study were 949
actually taking statins so the results cannot be viewed 950
as reliable. Becker at al then reported in a case-control 951
analysis involving 3637 PD patients and 3637 con- 952
trols that the long-term use of statins or fibrates was 953
not associated with a substantially altered relative risk 954
of developing PD [179]. 955
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The same year, a study of approximately 50,000956
Finnish citizens, with their baseline serum total957
cholesterols stratified into five groups, reported that958
those individuals with the highest levels of choles-959
terol were almost 90% more likely to develop PD960
than those with the lowest levels of cholesterol [180],961
concluding that, in subjects under 55 years of age,962
our ‘large prospective study suggests that high total963
cholesterol at baseline is associated with an increased964
risk of Parkinson’s disease’.965
A retrospective study involving a cohort of 419 PD966
patients, showed that in PD patients who received967
either a statin or a fibrate, their mean age of disease968
onset was delayed by nearly 9 years when com-969
pared with PD patients who were not taking any970
lipid-lowering treatment [181]. They also found the971
increase in the levodopa-equivalent daily dose over972
2 years was significantly smaller in the group tak-973
ing a statin (+24 mg) than in the matched control974
group (+212 mg) (p = 0.004), whereas the UPDRS975
motor score progression was similar. Their conclu-976
sion was that lipid-lowering drugs may have a disease977
modifying effect.978
The 2011 DATATOP study [182] then provided979
evidence that higher total serum cholesterol con-980
centrations may be associated with a modest slower981
clinical progression of PD. The same team at Harvard,982
using 12 years of patient follow-up, and following983
644 documented incident cases of PD, then reported984
[183] that regular use of statins was associated with985
a modest reduction in PD risk. They suggested that986
“the possibility that some statins may reduce PD risk987
deserves further consideration”.988
The following year Undela et al. [184] conducted989
a robust meta-analysis of published healthy subjects990
and found, across five separate case-control studies991
(n = 43,526) and three cohort studies (n = 1.4 million),992
that statin use reduced an individual’s risk of getting993
PD by 23% (p = 0.005), but no such effect was found994
for long-term statin use. They substantiated their find-995
ings by conducting further sensitivity analysis and996
concluded that their results ‘suggest a decreased rel-997
ative risk of PD in statin users as identified by a998
combined meta-analysis of eight observational stud-999
ies’. Friedman et al. [185] then reported their findings1000
following 94,308 (initially) non-statin users who did1001
not have PD. By the end of their study, there had1002
been 1035 incident cases of PD. Furthermore, 29,7141003
participants (31.5%) had started using statins for a1004
minimum of 6 months during the study period. This1005
statin use was associated with a significant decrease in1006
the incidence of PD (p = 0.001), while no association1007
was found between baseline LDL-C levels and PD 1008
risk. Friedman felt their results provided evidence 1009
relating to a lower incidence of PD among statin 1010
users. 1011
This contention was further supported by a report 1012
from Taiwan [186] following for several years 43,810 1013
individuals who had started taking a statin, and 1014
backed up by an excellent commentary by Tan and 1015
Tan, [187]. It was found that continuation of tak- 1016
ing lipophilic statins was associated with a decreased 1017
incidence of PD, whereas taking hydrophilic statins 1018
appeared not to generate this benefit. 1019
Then, Huang et al. [188] reported results of a 1020
prospective study involving 15,291 individuals with- 1021
out PD and mostly who were not statin users at study 1022
commencement. Over approximately a decade statin 1023
usage had increased to 11.2% of the study popula- 1024
tion, and there were 56 incident cases of PD. As 1025
in their 2011 paper [182] they reported that higher 1026
total cholesterol was associated with a lower risk of 1027
developing PD, even after adjustment for statin use. 1028
Unlike their earlier studies they calculated that statin 1029
use may be associated with a higher risk of acquiring 1030
PD which added further uncertainty to this topic, and 1031
also attracted considerable journalistic interest. 1032
To try to gain some clarity on whether statins were 1033
protective or not in terms of initially developing PD, 1034
Bai et al. [189] and Sheng et al. [190] both pub- 1035
lished extensive meta analyses of relevant results to 1036
date. Bai’s meta-analysis involved 3,513,209 indi- 1037
viduals and included 21,011 incident cases of PD. 1038
Sheng’s meta-analysis involved 2,787,249 individ- 1039
uals. The results of both studies were in complete 1040
agreement that statin use was associated with a much 1041
lower risk of PD (p = 0.001) and that sensitivity anal- 1042
yses confirmed the robustness of these results. They 1043
found that statin use was less protective of PD in 1044
North America than in other geographies, which is 1045
something that may account for some of the con- 1046
jecture and mixed results that had been published 1047
previously. Furthermore, and adding to this complex- 1048
ity in terms of confounding interpretation of statin 1049
use in the context of PD epidemiology, Clark et al. 1050
[191] found that the frequency of treatment success 1051
in dyslipidemia management was significantly lower 1052
in African American patients in the USA than in 1053
non-Hispanic white patients, while Yood at al [192] 1054
found that African American patients initiating statin 1055
therapy are less likely to achieve LDL goals, even 1056
after controlling for adherence differences and other 1057
factors, and suggested that this group may require 1058
different pharmacologic management. 1059
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Huang’s group then reported in 2016 [193] that1060
higher levels of LDL-cholesterol were associated1061
with improved executive set shifting and fine motor1062
scores in PD patients, but not in healthy controls. This1063
small study (64 PD cases) did not contain many statin1064
users to be meaningful on interpreting this aspect but1065
interestingly, they hypothesized from their results that1066
there may possibly be an association between choles-1067
terol and cognition that is nigrostriatal-based while1068
very fairly pointing out that they could not currently1069
ascertain whether this relationship was causative,1070
reverse-causative or a parallel process.1071
Earlier this year Huang’s group [194] used a large1072
US claims database of people who had chosen to1073
enroll in private healthcare insurance schemes in1074
order to interrogate this team’s earlier 2015 con-1075
tention [188] that statin use may be linked to a higher1076
risk of PD. This time they included 21,599 individu-1077
als who, during the period of their analysis generated1078
2322 incident cases of PD who, for statistical analy-1079
sis, were then matched with an identical number of1080
healthy controls. Consistent with several earlier stud-1081
ies, they found that higher levels of cholesterol was1082
associated with a lower risk of PD. They also reported1083
that the use of statins (especially lipophilic statins)1084
was associated with higher risk of PD.1085
Rozani et al. [195] recently published a 232,8771086
population-based cohort study of new statin users in1087
whom 2,550 developed PD during a mean follow-up1088
of 7.6 years. The study was unusual in that through-1089
out this time the researchers comprehensively made1090
multiple repeated measurements both of statin expo-1091
sure and LDL-levels. Contrary to Huang’s findings1092
[188, 194], and agreeing with the results of many1093
other studies [176–179, 181, 183–187, 189, 190] they1094
found no association between annual statin adherence1095
and PD risk regardless of age, or type of statin taken.1096
Understandably, those taking statins, or consider1097
taking a statin, to reduce their cardiovascular risk1098
want to know whether this choice would also bring1099
them an increased likelihood of developing PD? This1100
is a very different question to whether a statin might1101
represent a disease-modifying therapeutic for use in1102
patients who have already developed PD, and our1103
ongoing 2 year clinical trial involving approximately1104
200 PD patients seeks specifically to determine1105
whether Simvastatin slows PD progression.1106
As can be seen above, there have been several epi-1107
demiological studies investigating whether there may1108
be an association, protective or otherwise, of statin1109
use in relation to subsequent development of PD.1110
These have recently been evaluated in a systematic1111
review and meta-analysis by Bykov et al. [196] that 1112
helpfully discusses the methodological strengths and 1113
weaknesses of each these earlier epidemiological 1114
studies. It is fair to say that the methodologies uti- 1115
lized in the epidemiological papers cited above all 1116
have limitations. Association does not imply causa- 1117
tion. Bykov found that overall there seems to be a 1118
protective effect of statins against development of 1119
PD, but that if cholesterol levels are adjusted or, then 1120
this protective effect disappears, and there is no asso- 1121
ciation one way or the other with PD development. 1122
The authors also describe some of the limitations of 1123
epidemiological study design, including the ‘healthy 1124
user’ and ‘immortal time’ biases among others [197]. 1125
A brief description of the key findings from many 1126
of the various types of epidemiological studies that 1127
have attempted in recent years to determine whether 1128
the use of statins is positively or negatively associated 1129
with PD risk are summarized in Table 1. 1130
With regard to Huang’s most recent publication 1131
suggesting that Simvastatin may facilitate develop- 1132
ment of PD [194], there are some key limitations 1133
which merit highlighting: large sectors of the pop- 1134
ulation were not represented in the database that was 1135
analyzed (particularly the elderly, i.e., over 65 s, were 1136
excluded); and only those with private health insur- 1137
ance were included. It is possible that some patients 1138
in this study were misdiagnosed because the clinical 1139
details of the participants, and diagnostic confirma- 1140
tion, was not available to the researchers. The authors 1141
found that PD was more likely to be diagnosed within 1142
the first year or so of starting Simvastatin. How- 1143
ever, it is well acknowledged that PD starts at least 5 1144
years, if not 10 years before diagnosis; it has also 1145
been demonstrated by others that healthcare con- 1146
tacts increase in the year or two prior to diagnosis, 1147
which could be what led to their being prescribed 1148
a statin. It is well known that vascular risk factors 1149
increase risk of dementia, and it would not be unrea- 1150
sonable to suppose that the same might hold true for 1151
other neurodegenerative diseases. It is likely that most 1152
people taking a statin were started on it because of 1153
their vascular risk, and that this might have been the 1154
contributory factor that was identified in the study. 1155
Indeed, a UK cohort study has demonstrated worse 1156
PD severity with increased cardiovascular risk, and 1157
underutilization of statins in the PD population [198]. 1158
The association of cholesterol and statins as risk 1159
factors for PD development has recently been dis- 1160
cussed in a Lancet Neurology review by Ascherio 1161
& Schwarzschild [104], which concluded that any 1162
possible association remains uncertain. 1163
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Table 1
Key findings from various epidemiological studies that have attempted to determine whether the use of statins is positively or negatively
associated with PD risk
Reference and Research team Study Type & Size Results Statistics and additional
information
Wolozin et al. [176] Retrospective analysis of VA
database of 4.5 million
subjects, which included
700,000 SV users
Protective. SV ‘strongly
protective’ of PD risk
SV use reduced the Hazard Ratio
(0.51) p < 001
Huang et al. [178] Case control study involving 124
PD cases and 112 controls
Protective. Use of
cholesterol-lowering drugs
(primarily statins) in this study
group was associated with a
lower occurrence of PD
Odds Ratio = 0.36–0.41
Wahner et al. [177] 312 PD cases versus 343
controls. Population-based case
control study of incident PD
Protective. 3 of 5 different statins
were associated with
approximately a 55% reduction
in PD risk
Statistically significant Risk
Reduction for SV, AV, LV, but
not for PV. Odds Ratios
(p < 0.01) were 0.38, 0.39 and
0.27, respectively
Becker et al. [179] Case-control observational
analysis involving 3,637 PD
patients (378 of whom had or
were taking statins), and 3,637
controls
No difference found between PD
patients and controls
Odds Ratio = 1.06
Mutez et al. [181] Retrospective analysis of a cohort
of 419 PD patients
Protective. Mean age of onset of
PD delayed 9 years by statin
use
Levodopa-equivalent daily dose
also reduced in the group
taking a statin
Gao et al. [183] Prospective study of 129,066
healthy subjects, 644 of whom
developed PD over 12 years of
follow-up
Protective. Regular use of statins
was associated with a modest
reduction in PD risk
Relative Risk was 0.74, p < 0.05,
and for subjects under 60 years,
Relative Risk was 0.31,
p = 0.02
Undela et al. [184] Meta-analysis, combining 5 case
control studies and 3 cohort
studies which studied 1.4
million subjects including
15,102 PD cases
Protective. Statin use over a 2–14
year follow-up reduced risk of
PD by 23%
Relative Risk = 0.77, p = 0.005
Friedman et al. [185] 94,308 subjects without PD or
statin use at baseline. Over 7
years, 1035 developed PD, and
29,714 took statins for at least
6 months
Protective. Statin use up to 2.5
years of follow-up in 15,394
patients was associated with a
significantly reduced risk of PD
Odds Ratio for reduced risk of
PD = 0.69, p < 0.001
No association noted between
baseline LDL-C levels and PD
risk
Lee et al. [186] Study followed 43,810 statin
users without PD, 1,985 of
whom went on to develop PD
Protective. Use of lipophilic
statins, either SV or AV, each
reduced the incidence of
emergent PD
SV and AV significantly reduced
the Hazard Ratio (0.23–0.42)
for PD risk depending on age
and gender. The incidence rate
for PD was 1.68 and 3.52 per
1,000,000 person-days for
lipophilic and hydrophilic
statins, respectively
Huang X et al. [188] Prospective study of 15,792
subjects over 9 years, 106 of
whom developed PD while
another 187 subjects may have
developed PD but this could
not be clinically confirmed
Disadvantageous. Statin use was
associated with a higher risk
for PD when adjusted for
cholesterol levels
Odds Ratio = 2.30, p < 0.05 In
addition, higher total
cholesterol was associated with
lower risk for PD after
adjustment for statin use
Liu et al. [194] Retrospective case control
analysis involving 2,322
probable incident PD cases and
2,322 controls. Same research
team as 188
Disadvantageous. Statin usage
was significantly associated
with PD risk
Strongest associations with PD
risk was for lipophilic statins
(Odds Ratio = 1.58,
p < 0.0001), whereas for
hydrophilic statins (Odds
Ratio = 1.19, p = 0.25)
(Continued)
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Table 1
(Continued)
Reference and Research team Study Type & Size Results Statistics and additional
information
Rozani et al. [195] Population-based cohort of statin
initiators. 232,877 new statin
users were followed for 7+
years, and in whom there were
2,550 emergent cases of PD
Statin adherence over time did
not affect PD risk
All-risk estimates were close to
unity (except for a slightly
reduced PD risk: Hazard
Ratio = 0.77 among women
aged 40–45 with LDL-C level
160 mg/dl at baseline) Results
unaffected by whether statins
were lipophilic or hydrophilic
Bai et al. [189] Meta-analysis, combining 5 case
control studies and 6 cohort
studies which studied 3.5
million subjects (1.1 million
statin users), and including
21,011 incident cases of PD
Protective. Statin use was
associated with a reduced risk
of PD
Because of the low incidence of
PD, the authors felt distinctions
among RR, HR, and OR could
be ignored, allowing combined
case-control and cohort studies,
and calculated the summary
Relative Risks and 95% CIs.
Relative Risk for reduced PD
risk was 0.81, p = 0.002
Bykov et al. [196] Meta-analysis, of ten eligible
epidemiological studies
Protective, but only in the six
studies analyzed that did not
adjust for cholesterol.
Protective effect of statins
against PD risk, Relative
Risk = 0.75 95%CI: 0.60 to
0.92
No protective effect was observed
among the four studies that
adjusted for either cholesterol
or hyperlipidemia Relative
Risk = 0.91; 95%CI 0.68 to
1.22
Sheng et al. [190] Meta-analysis, of 11 studies
(2,787,249 subjects) including
5 case-control and 6 cohort
studies
Protective. Use of statins was
associated with a significant
reduction in risk of developing
PD
Adjusted Relative Risk = 0.74,
95% CI 0.62 to 0.90, P < 0.001
Results, and outcomes measures used, are as described by the respective authors. SV, Simvastatin; AV, Atorvastatin; LV, Lovastatin; PV,
Pravastatin.
In conclusion, we reiterate, whether PD risk is1164
increased or decreased by taking a statin to lower1165
cardiovascular risk (and a clear future demonstration1166
of the reality of this would be valuable and welcome),1167
that the testing of a statin to treat PD neurodegenera-1168
tion in patients who already have established PD is a1169
completely separate and unrelated question. It there-1170
fore remains highly reasonable to pursue Simvastatin1171
in a randomized clinical trial to test its disease-1172
modifying potential in a population of PD patients1173
(see biochemical/pharmaceutical rationale described1174
earlier). In this Simvastatin trial [7] we are measur-1175
ing PD severity and so will pick up whether or not1176
the rate of PD progression is affected by Simvastatin,1177
hopefully in a positive direction as that is the point1178
of the trial. We are carefully monitoring for adverse1179
events and at the end of the study in 2020 we will1180
finally be able to evaluate the unblinded data.1181
DESCRIPTION OF CURRENT LCT1182
CLINICAL TRIAL OF SIMVASTATIN1183
No drug has yet been shown to slow or reverse1184
the neurodegenerative process of PD. All currently1185
licensed therapies act as symptom-relieving agents 1186
but have a limited lifespan of effectiveness because 1187
of continued neuronal loss. The purpose of this study, 1188
as mandated by the International PD Linked Clin- 1189
ical Trials Committee [6], is to determine whether 1190
Simvastatin, a widely used cholesterol-lowering 1191
drug (statin) with an excellent safety profile, is 1192
capable of reducing the rate of neurodegenerative 1193
decline in patients with PD. Details of this clin- 1194
ical trial are described on the US clinical trials 1195
website [7]: https://clinicaltrials.gov/show/NCT027 1196
87590. 1197
Briefly, after considerable discussion about how 1198
best to configure an appropriate long-term disease- 1199
modifying trial in PD patients (rather than a 1200
symptomatic study), a randomized, double-blind, 1201
placebo-controlled, two year study was chosen, to 1202
be conducted in idiopathic PD patients who, at study 1203
commencement, had been characterized as Modified 1204
Hoehn and Yahr stage ≤ 3.0 in the ON medication 1205
state. It was made a requirement for entry into the 1206
trial that they were on dopaminergic treatment with 1207
wearing-off phenomenon. 1208
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Participants are randomly allocated to one of two1209
treatment groups. In one group, participants are given1210
capsules of Simvastatin to take orally (by mouth) for1211
24 months.1212
The other group receives placebo capsules to take1213
orally for 24 months. At the start of the study, when1214
they receive their medication, participants complete1215
a number of questionnaires and motor (movement)1216
tests (a walking test and a finger tapping test). Par-1217
ticipants in both groups also attend a further 6 clinic1218
visits after 1, 6, 12, 18 and 24 and 26 months, where1219
they are asked about their health and any medication1220
they are taking, as well as repeating the question-1221
naires and motor tests. For 4 of the clinic visits, having1222
omitted their usual PD medication that day, the par-1223
ticipants are asked to attend in the ‘OFF medication’1224
state so that the researchers can get a true picture of1225
their disease without it being masked by their normal1226
medication.1227
The Simvastatin trial is a 198 patient, 23 Centre,1228
Phase II, randomized, placebo-controlled, double-1229
blinded study, officially titled ‘Simvastatin as a1230
Neuroprotective Treatment for Parkinson’s Disease:1231
a Double-blind, Randomised, Placebo Controlled1232
Futility Study in Patients of Moderate Severity’.1233
The primary outcome measure is Change in MDS-1234
UPDRS part III (OFF) score, and the duration of1235
treatment is 24 Months. The Secondary Outcome1236
Measures include MDS-UPDRS total score in the1237
practically defined ON state, MDS-UPDRS part II1238
subscale score in the practically defined ON state,1239
Timed motor tests - finger tapping and timed walk1240
test, Timed Motor Tests include evaluating the num-1241
ber of hand taps that an individual can perform1242
within 30 seconds and a timed walk test. In addition,1243
the following rating scales are used to evaluate the1244
study participants: Montgomery and Asberg Depres-1245
sion Rating Scale (MADRS), The Addenbrooke’s1246
Cognitive Assessment-III (ACE-III), Non-Motor1247
Symptom assessment scale (NMSS), Parkinson’s1248
disease Questionnaire (PDQ-39), Changes in PD1249
medication as measured by levodopa-equivalent dose1250
(LED), Cholesterol levels (total, HDL, total/HDL1251
ratio), King’s PD pain scale (KPPS), EuroQoL 5D-1252
5L health status questionnaire (EQ-5D-5L), Safety1253
and tolerability of trial medication by adverse1254
events (AEs) review, and Incidence of diabetes1255
mellitus.1256
Active comparator: A one month low dose phase1257
of 40 mg oral Simvastatin daily is followed by a 23-1258
month high dose phase of 80 mg oral Simvastatin1259
daily and a final two month phase off trial medication.1260
Matched Placebo Comparator: A one month low dose 1261
phase of 40 mg matched placebo daily is followed 1262
by a 23 month high dose phase of 80 mg matched 1263
placebo daily and a final two month phase off trial 1264
medication. 1265
Outline of choices made about the Simvastatin 1266
trial 1267
Patient population 1268
We elected to recruit patients in mid-stage disease, 1269
H&Y < or = 3 in the ON state, but who had developed 1270
motor fluctuations. The reason for this was two-fold. 1271
First, we felt that the trial findings would be of rel- 1272
evance to people living with PD today. Second, the 1273
presence of wearing off reduces the degree of het- 1274
erogeneity in the study population, particularly for 1275
ensuring, as much as possible, consistency in the 1276
‘practically-defined off’ state used for the primary 1277
outcome measure. 1278
Study sites 1279
We selected a multi-center design as it would not 1280
be possible to recruit the required number of partic- 1281
ipants from a single center. Within the UK we have 1282
an established Clinical Research Network that facili- 1283
tates study delivery within centers experienced in PD 1284
clinical study delivery. The multi-center nature of the 1285
study does introduce issues relating to quality con- 1286
trol, particularly with regard to rater experience and 1287
training. We therefore carried out feasibility assess- 1288
ments with sites expressing interest, stipulating the 1289
study requirements in terms of rater uniformity for 1290
the study duration, the need for an independent rater 1291
(separate from the rest of study delivery), rater expe- 1292
rience and training (kindly provided by the MDS for 1293
this study). In addition, the study co-ordinating cen- 1294
ter has robust data management and site monitoring 1295
processes to ensure quality data collection across all 1296
sites. 1297
Dose of Simvastatin chosen 1298
We chose to use a dose of 80 mg of Simvastatin 1299
for this study, as this was the dose shown to have 1300
an excellent protective effect in the MS STAT trial 1301
involving treating Multiple Sclerosis patients [135, 1302
199]. There are safety concerns regarding the use of 1303
high dose Simvastatin, particularly in the elderly. The 1304
overall risk of statin-induced myopathy is approxi- 1305
mately 1%. We have introduced robust guidance and 1306
safety procedures into the protocol to mitigate this 1307
risk. 1308
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Choice of selected duration of clinical trial1309
Study duration was chosen as 24 months to max-1310
imize the potential for differences in progression1311
between placebo and active treatment group. It is1312
known that the placebo effect in PD studies is large1313
and sustained. In addition, with a relatively small1314
sample size and a clinically heterogeneous condition,1315
it is important to allow sufficient time for measurable1316
disease progression across the study population.1317
Choice of primary patient outcome1318
Choice of primary outcome measure was the OFF1319
state MDS-UPDRS part III as this is the most likely to1320
correlate with underlying disease severity and there-1321
fore be indicative of disease progression. This does1322
not reflect clinical meaningfulness for patients whose1323
OFF state UPDRS score will be improved by symp-1324
tomatic medication; however, demonstrating clinical1325
utility is not the purpose of this preliminary study. If1326
this study suggests that Simvastatin does have poten-1327
tial as a neuroprotective agent, then a further Phase1328
III study can evaluate impact on clinically meaningful1329
outcomes, such as patient reported measures, quality1330
of life measures, and cognitive decline.1331
Other design aspects1332
In order to distinguish a protective effect from a1333
potential symptomatic effect a washout design was1334
chosen with a 2-month washout period after the end1335
of the 24-month treatment period. The half-life of1336
Simvastatin is less than 5 hours, and so this period1337
provides sufficient time for drug elimination.1338
DISCUSSION1339
The international PD linked clinical trials com-1340
mittee, based on a range of evidence compiled1341
into a detailed dossier, and followed by extensive1342
committee discussions, agreed in 2012 to prioritize1343
Simvastatin to enter a trial in PD patients to assess its1344
potential as a disease-modifying therapy [6]. Clini-1345
cal trials of potential neuroprotective agents in PD1346
are difficult to design. This is partially because of1347
the variability in disease phenotype and rate of pro-1348
gression, and also, the potential confounding factor1349
of a symptomatic response. In addition, there is no1350
reliable biomarker for disease progression. The Inter-1351
national PD Linked Clinical Trial committee is tasked1352
to analyze potential new target therapies for PD and1353
for which the biochemical evidence indicates the1354
likelihood that they may have benefit to slow, halt1355
or reverse disease progression in patients with PD. 1356
This large global committee of PD experts, many 1357
of whom have extensive experience in PD trials and 1358
their design, is coordinated by The Cure Parkinson’s 1359
Trust. The detailed biochemical, physiological, and 1360
pharmaceutical evidence available to the committee 1361
in 2012 which led them to choose to prioritize Sim- 1362
vastatin to enter a disease-modifying clinical trial is 1363
summarized in the first section of the current paper, 1364
with very substantial updating to October 2017. It is 1365
interesting to observe that the rationale, then in 2012, 1366
for taking Simvastatin into a PD trial to assess its 1367
disease-modifying potential (in fact, there are several 1368
separate mechanistic rationales as outlined above) 1369
has continued to strengthen over those 5 years on all 1370
biochemical and physiological fronts. Another recent 1371
review by Saeedi Saravi et al. [200] also summarizes, 1372
but more generally across several neurodegenerative 1373
diseases, the biochemical and pharmaceutical mech- 1374
anisms of action of how statins may be beneficial 1375
in the management of these conditions. In their dis- 1376
cussion of the treatment of multiple sclerosis they 1377
explore research into how immunomodulatory and 1378
anti-inflammatory properties of statins may help- 1379
fully unite for therapeutic benefit [201–203] and 1380
this may also be of direct relevance to the long- 1381
term management of PD. This is especially poignant 1382
since Simvastatin has already shown encouraging 1383
long-term clinical results in patients with multiple 1384
sclerosis [135, 199, 204], and a major Phase III study 1385
involving almost 1200 patients being given high dose 1386
Simvastatin (80 mg daily) will commence in the com- 1387
ing months. We have long established strong lines 1388
of communication between those involved with the 1389
multiple sclerosis (MS-STAT) and Simvastatin (PD 1390
STAT) trials. 1391
Taking the example, also conceptually relevant 1392
to PD, of the costs of some of the newer multi- 1393
ple sclerosis (patented) therapeutics that are pursuing 1394
disease-modification objectives, several of these cur- 1395
rently exceed $75,000 per patient per year [205]. 1396
By contrast, the annual cost per patient of 80 mg 1397
Simvastatin (now unpatented) is $37 per year [206], 1398
although that is not to say that the cost effectiveness 1399
of those high value therapies render them financially 1400
unusable [207–209], as this can vary across patient 1401
subgroups which in turn means that direct therapeu- 1402
tic, or even financial, comparisons with Simvastatin 1403
cannot always readily be made. However, there may 1404
be situations in the future where low cost unpatented 1405
drugs like Simvastatin may look a very attractive 1406
therapeutic alternative for healthcare providers, while 1407
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the patient perspective can be somewhat different1408
and must also be taken in to account [210] because1409
health economic algorithms currently used often miss1410
substantial additional social value.1411
The first, biochemical, section of this paper demon-1412
strates that Simvastatin acts on a number of separate,1413
distinct intracellular processes, each of which appear1414
of relevance to the long-term management of PD.1415
These remain highly active research topics and we1416
eagerly anticipate developments into this growing1417
insight. When a repurposed therapeutic such as Sim-1418
vastatin, has multiple pleiotropic effects, all or any1419
of which may be clinically beneficial, there some-1420
times comes a point when one may just acknowledge1421
we cannot identify a clear therapeutic target (because1422
there are so many positively-orientated candidate1423
modes of action), and go ahead and test it in the1424
clinic. To quote John Overington from Benevolen-1425
tAI, ‘although the concept of a single drug target1426
is a natural one for researchers in the field, there1427
are substantial operational difficulties in consistently1428
mapping this target concept to specific genes and gene1429
products’ [211]. Clearly, having a strong and exten-1430
sive safety record has helped us move Simvastatin1431
into a long-term trial in PD patients to explore its1432
disease-modifying potential. We anticipate our cur-1433
rent Simvastatin trial in PD patients will finish in1434
2020.1435
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